Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vidicitamab + trastuzumab + tislelizumab vs CAPOX + trastuzumab ± pembrolizumab in HER2-positive advanced gastric/GEJ cancer
CTR20254827Phase 3Active
- Sponsor
- RemeGen
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of disitamab vedotin, trastuzumab, tislelizumab, oxaliplatin, capecitabine in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by RemeGen. Started Jan 2026; status: active.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20254827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254827.